Buffalo, N.Y.-based Roswell Park Comprehensive Cancer Center, University of Rochester (N.Y.) Wilmot Cancer Institute and New York City-based Mount Sinai, NYU Langone Health and Weill Cornell Medicine have established the Empire State Cellular Therapy Consortium.
Member organizations will have expanded access to resources across the consortium, including Roswell Park’s $98 million GMP Engineering & Cell Manufacturing Facility, according to a July 10 news release from the cancer center.
“Consortium members expect to open several clinical trials within the next two years,” the release said. “[Members] will also collaborate to expand patients’ access to standard-of-care cell therapies already approved by the FDA.”
The consortium officially launched in February with Marco Davila, MD, PhD, senior vice president and associate director of translational research at Roswell Park, serving as the consortium’s inaugural chair.
Leave a Reply